UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data

By: via Benzinga
In a report published Wednesday, Nomura analyst Ian Somaiya reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.